Subject: Will Brexit embrace Medtech innovation?

INSIDE THIS NEWSLETTER

  • Series A Fundraising

  • EIT Health Investor Network Gold Company

  • New Lab Space

  • LSX World Congress

  • New Team Member

  • NIHR Webinar: Accelerating MedTech Evidence

  • Meet Our Employee

Post-Brexit Era

Will Brexit embrace innovation?

The Transition Period is over, and Brexit has been finalised. As a UK based start-up with several European partners and a global outlook, we are still analysing exactly what impact Brexit is going to have for us. We hope that the exchange of good between the UK and the EU will remain smooth, efficient, and cost-effective. We have seen some delays at the borders when buying some supplies from the EU, but hopefully, these are just teething problems. We would also encourage the government to consider maintaining regulatory alignment with the EU. Securing regulatory approval for a product such as ours is expensive and time-consuming, so it would certainly be an advantage if the UK market will accept the European CE mark. We also see some opportunities – we are excited to see what new trade deals and export opportunities might emerge now that we are no longer in the EU, particularly in emerging markets. If 2020 reminded us of anything it is that predicting the future is a fool’s errand! So you won’t see any predictions for 2021 from us, but let’s hope that it’s a good one!

 

Series A Fundraising

We are looking for experienced institutional investors to participate in our Series A, which will support pivotal clinical trials for our anti-IL-6 Magnetic Blood Filtration products. Please get in touch to request more information and a company deck.

Get in touch to get more information: info@medisieve.co.uk

 

EIT Health Investor Network Gold Company

MediSieve has been promoted to being a Gold Company within the EIT Health Investor Network the highest possible rank. The EIT Health Investor Network connects qualified companies seeking early-stage funding with the first pan-European consortium of more than 80 investors. The gold label distinguishes us as a strong project with a high potential for growth. This will provide us with new mentoring and investment opportunities - a big thank you to EIT Health! Follow us on LinkedIn for the most recent news.


 

Expanding Our Lab Space

The start of the year has been full of exciting changes. In addition to making significant progress in research, our team has moved out of our shared laboratory and into a new, fully dedicated laboratory to meet our R&D needs. This gives us full control over safety and equipment availability, increasing and improving both safety and experimental capacity. Follow us on Twitter to learn more about our team's life!

 

MediSieve at the LSX World Congress

We continue to engage with the wider biotech and medtech communities. This month, we digitally attended one of the major investor conferences, the LSX World Congress. The event brings together innovative start-ups, life sciences giants, investors and top-tier service companies. Check our website to see where to meet us.

 

Our Team is Growing

This February, we welcomed another new talented and driven team member! Serena Hansmann joined MediSieve as a Lab Technician. She will be using her past research experience to support our team in various projects, particularly the development and validation of our magnetic beads. Learn more about the rest of our team here.

 

MediSieve on the Panel in a Webinar With NIHR and Device Access UK

In February, Device Access UK, together with the National Institute for Health Research (NIHR), held a webinar on MedTech evidence generation for the NHS. Our CEO, George Frodsham, was invited to join the conversation and talk about MediSieve's perspective on the matter. You can watch the recording here.

MediSieve Faces 

MediSieve is working on creating a novel blood filtration technology that will be the first of its kind. But what truly sets us apart from other companies is our people. Meet the individuals who are transforming our dream of eliminating the burden of blood-borne diseases into reality:

What are your responsibilities within MediSieve?

- I am involved in the sepsis-focused E. coli project. Within the biochemistry and immunology department, we are carrying out a wide range of experiments to assess the biocompatibility and removal efficiency of E. coli-targeting beads, which have the potential to magnetically filter E. coli from a patient's blood under MediSieve's magnetic blood filtration system.

What originally drew you to MediSieve?
- Reading about MediSieve for the first time, I was intrigued by how their "dialysis-like" technology uses the power of magnetics to selectively remove harmful substances from the blood. One of my family members had undergone dialysis therapy for many decades and hearing about a similar, more innovative technology with the possibility to overcome side effects and optimise removal was incredibly exciting.

What do you like most about working here?
- I love the deep sense of community within the company, and how each employee is clearly making a tangible difference. When I first started to work for MediSieve, I thought that my impact would be minimal, however, the weekly company discussions, lab meetings and the overall friendly yet hard-working atmosphere served as a catalyst for me to render valuable results.

How did the COVID-19 outbreak affect your personal and work life?
- I used to live with my flatmate (and best friend) last year. Now due to the pandemic, she is unable to come back and is currently studying online in Hong Kong, which means that I have to live alone! Luckily, I still have friends and family in London, so it is not a big problem. In terms of work-life, I have been extremely fortunate to work with little to no disruption during these times. Safety measures are easily implemented within the company (be it office or lab), so I have been very lucky in that sense.


Powered by:
GetResponse